To achieve its goal of being a leader in medical dermatology, Denmark’s LEO Pharm today announced – in early 2023 - a significant shift in R&D to a research model, which aims at driving the early-stage pipeline with externally sourced innovation.
Equally important for LEO Pharma is to maximize the value to patients of our three assets in late-stage development: tralokinumab, delgocitinib and IL-22R, ensuring competitive labels and the fastest possible approvals and launches to bring first- and best-in-class solutions to patients.
To support these two critical pillars, LEO Pharma today announced a split of its research and development (R&D) organization into two distinct areas, both represented in the global leadership team (GLT). The two GLT members - a chief scientific officer and a chief development officer – will both report to chief executive Christophe Bourdon.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze